ArticleMolecular diversity2026
Ligand-based graph neural network, molecular dynamics and biological evaluation for identification of potential FGFR1 kinase inhibitors.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Currently approved FGFR1 kinase inhibitors still suffer from several disadvantages, including significant toxicities and adverse effects. To identify promising FGFR1 inhibitors, we developed a ligand-based graph neural network (GNN) virtual screening model and conducted high-throughput screening of FGFR1 kinase inhibitors using this model. Compared with traditional models, our model reveals better performance (Accuracy of 0.9186, AUC of 0.964). The model was employed to conduct preliminary screening of a 14-million-compound library. Subsequently, multi-stage screening was performed, including two rounds of molecular docking and two stages of molecular dynamics simulations. This approach identified five compounds capable of forming stable hydrogen bond interactions with FGFR1 and strong binding free energy (between − 28.23 and − 34.24 kcal/mol), which exhibited adequate binding stability in 300 ns molecular dynamics simulation. Four of the compounds were then subjected to biological evaluation, which revealed that they exhibited varying degrees of inhibitory activity against FGFR1 kinase. Notably, two of these compounds demonstrated excellent inhibitory activity ([Formula: see text]M and 3.3 [Formula: see text]M, respectively). In summary, this study developed a high-throughput virtual screening model for FGFR1 kinase inhibitors based on graph neural networks, providing novel lead compounds for the research of FGFR1 kinase inhibitors.
Indexed as
Identifiers
41764695What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.